Is there a Bearish outlook for Natera, Inc. (NASDAQ:NTRA) this week?

Natera, Inc. (NASDAQ:NTRA) Logo

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

Among 3 analysts covering Natera (NASDAQ:NTRA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Natera had 5 analyst reports since February 21, 2019 according to SRatingsIntel. On Tuesday, June 25 the stock rating was maintained by Canaccord Genuity with “Buy”. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, August 8. Piper Jaffray maintained it with “Buy” rating and $23 target in Monday, March 11 report. On Monday, March 11 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock of Natera, Inc. (NASDAQ:NTRA) has “Buy” rating given on Thursday, February 21 by Robert W. Baird. Below is a list of Natera, Inc. (NASDAQ:NTRA) latest ratings and price target changes.

08/08/2019 Broker: Canaccord Genuity Rating: Buy Old Target: $32.0000 New Target: $36.0000 Maintain
25/06/2019 Broker: Canaccord Genuity Rating: Buy New Target: $32 Maintain
11/03/2019 Broker: Canaccord Genuity Rating: Buy New Target: $25 Maintain
11/03/2019 Broker: Piper Jaffray Rating: Buy New Target: $23 Maintain
21/02/2019 Broker: Robert W. Baird Rating: Buy New Target: $21 Maintain

The stock decreased 7.85% or $2.33 during the last trading session, reaching $27.35. About 433,385 shares traded. Natera, Inc. (NASDAQ:NTRA) has risen 22.47% since August 14, 2018 and is uptrending. It has outperformed by 22.47% the S&P500.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. The company has market cap of $1.92 billion. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrierÂ’s children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. It currently has negative earnings. The firm also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

More notable recent Natera, Inc. (NASDAQ:NTRA) news were published by: Benzinga.com which released: “76 Biggest Movers From Yesterday – Benzinga” on August 13, 2019, also Nasdaq.com with their article: “Natera (NTRA) Shares Cross Below 200 DMA – Nasdaq” published on April 17, 2019, Seekingalpha.com published: “Natera up 11% on draft reimbursement for Prospera test – Seeking Alpha” on March 28, 2019. More interesting news about Natera, Inc. (NASDAQ:NTRA) were released by: Prnewswire.com and their article: “Natera Announces Pricing of Follow-On Offering – PRNewswire” published on April 17, 2019 as well as Prnewswire.com‘s news article titled: “Publication Demonstrates Unique Ability of Panorama Test to Determine Zygosity in Twin Pregnancies – PRNewswire” with publication date: August 05, 2019.

Natera, Inc. (NASDAQ:NTRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.